Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018.

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Pasadena. CA | Posted on November 27th, 2018

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6744427.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6744427.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

ULVAC Launches Revolutionary PZT Piezoelectric Thin-film Process Technology and HVM Solution for MEMS Sensors/Actuators: Enabling Reliable, High-quality Film Production for Next Generation Devices August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

Nanomedicine

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

Probing the Origin of Alzheimer’s . . . with Transistors: Novel high-sensitivity detector could aid in early diagnosis August 15th, 2019

Announcements

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

ULVAC Launches Revolutionary PZT Piezoelectric Thin-film Process Technology and HVM Solution for MEMS Sensors/Actuators: Enabling Reliable, High-quality Film Production for Next Generation Devices August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results July 25th, 2019

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.76 as of March 31, 2019; an Increase of 4.5% From December 31, 2018 May 1st, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

Events/Classes

Kavli Lectures: Innovation by evolution and harnessing the quantum mechanics of the hydrogen bond August 15th, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results July 25th, 2019

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences June 2nd, 2019

Nanobiotechnology

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Probing the Origin of Alzheimer’s . . . with Transistors: Novel high-sensitivity detector could aid in early diagnosis August 15th, 2019

Damaged hearts rewired with nanotube fibers: Texas Heart doctors confirm Rice-made, conductive carbon threads are electrical bridges August 14th, 2019

Nanoparticles’ movement reveals whether they can successfully target cancer: Targeting nanoparticles rotate faster and move across larger areas August 9th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project